PL325457A1 - Humanised antibodies effective against human fas - Google Patents

Humanised antibodies effective against human fas

Info

Publication number
PL325457A1
PL325457A1 PL98325457A PL32545798A PL325457A1 PL 325457 A1 PL325457 A1 PL 325457A1 PL 98325457 A PL98325457 A PL 98325457A PL 32545798 A PL32545798 A PL 32545798A PL 325457 A1 PL325457 A1 PL 325457A1
Authority
PL
Poland
Prior art keywords
effective against
against human
human fas
humanised antibodies
antibodies effective
Prior art date
Application number
PL98325457A
Inventor
Nobufusa Serizawa
Hideyuki Haruyama
Tohru Takahashi
Kaori Nakahara
Shin Yonehara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of PL325457A1 publication Critical patent/PL325457A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
PL98325457A 1997-03-21 1998-03-20 Humanised antibodies effective against human fas PL325457A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6793897 1997-03-21

Publications (1)

Publication Number Publication Date
PL325457A1 true PL325457A1 (en) 1998-09-28

Family

ID=13359383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98325457A PL325457A1 (en) 1997-03-21 1998-03-20 Humanised antibodies effective against human fas

Country Status (15)

Country Link
EP (1) EP0866131A3 (en)
KR (1) KR19980080514A (en)
AR (1) AR012148A1 (en)
AU (1) AU736287B2 (en)
BR (1) BR9800937A (en)
CA (1) CA2232828A1 (en)
CZ (1) CZ85898A3 (en)
HU (1) HUP9800613A3 (en)
ID (1) ID20065A (en)
IL (1) IL123756A0 (en)
NO (1) NO981272L (en)
NZ (1) NZ330004A (en)
PL (1) PL325457A1 (en)
TR (1) TR199800517A2 (en)
ZA (1) ZA982371B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
AU4772299A (en) * 1998-06-18 2000-01-05 Karolinska Innovations Ab Fas peptides and antibodies for modulating apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
ES2202039T3 (en) * 1999-01-11 2004-04-01 Leadd B.V. USE OF APOPTOSIS INDUCTIVE AGENTS IN THE PREPARATION OF MRDICAMENTTO FOR THE TREATMENT OF AUTOIMMUNITY DISEASES.
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
AU761544C (en) * 1999-05-24 2004-02-12 Sankyo Company Limited Medicinal compositions containing anti-Fas antibody
EP1485130A4 (en) * 2002-02-21 2006-11-22 Univ Duke Reagents and treatment methods for autoimmune diseases
EP1506237A1 (en) * 2002-05-17 2005-02-16 Fusion Antibodies Limited Treatment of cancer by the use of anti fas antibody
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP4124480B2 (en) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
CA2174132A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
NO971448L (en) * 1996-04-01 1997-10-02 Sankyo Co Recombinant anti-Fas antibodies and DNA for these

Also Published As

Publication number Publication date
KR19980080514A (en) 1998-11-25
AU736287B2 (en) 2001-07-26
NO981272D0 (en) 1998-03-20
HU9800613D0 (en) 1998-05-28
AR012148A1 (en) 2000-09-27
HUP9800613A2 (en) 1999-02-01
IL123756A0 (en) 1998-10-30
NO981272L (en) 1998-09-22
HUP9800613A3 (en) 2001-04-28
CA2232828A1 (en) 1998-09-21
EP0866131A3 (en) 1999-12-15
TR199800517A3 (en) 1998-10-21
EP0866131A2 (en) 1998-09-23
NZ330004A (en) 1998-10-28
BR9800937A (en) 2000-01-11
ZA982371B (en) 1998-09-28
CZ85898A3 (en) 1998-10-14
TR199800517A2 (en) 1998-10-21
AU5937598A (en) 1998-10-15
ID20065A (en) 1998-09-24

Similar Documents

Publication Publication Date Title
IL136335A0 (en) Monoclonal human natural antibodies
AU1462300A (en) Human pan-hcv human monoclonal antibodies
HK1096974A1 (en) Antibody against human parathormone related peptides
EP1071458A4 (en) Humanized antibody and uses thereof
EP0977991A4 (en) Monoclonal antibodies to human cd6
PL349266A1 (en) Human monoclonal antibodies to ctla-4
IL128406A0 (en) Monoclonal antibodies
PL330111A1 (en) Concentyratyed antibody preparation
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
GB9422383D0 (en) Antibodies
PL314908A1 (en) Humanised antibodies and their application
GB9603256D0 (en) Antibodies
PT1818343E (en) Antibodies against human il-12
HUP0003762A3 (en) Adipocyte-specific protein homologs
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
EP1178829A4 (en) Human monoclonal antibody
PL325457A1 (en) Humanised antibodies effective against human fas
HUP9800744A3 (en) Antibodies against fas-antigene
EP0977590A4 (en) Human monoclonal antibodies
ZA9510195B (en) Monoclonal antibody fragments having immunosuppressant activity
GB9718911D0 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
PL329866A1 (en) Monoclonal antibody against human mp52
GB9726147D0 (en) Antigens
GB9419312D0 (en) Polyclonal antibodies and their use